Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Issue 7 (3rd July 2017)

• Record Type: Journal Article
• Authors: Shanafelt, Tait D.; Parikh, Sameer A.; Noseworthy, Peter A.; Goede, Valentin; Chaffee, Kari G.; Bahlo, Jasmin; Call, Timothy G.; Schwager, Susan M.; Ding, Wei; Eichhorst, Barbara; Fischer, Kirsten; Leis, Jose F.; Chanan-Khan, Asher Alban; Hallek, Michael; Slager, Susan L.; Kay, Neil E.
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 7(2017)
• Page Start: 1630
• Page End: 1639
• Publication Date: 2017-07-03
• Subjects: Chronic lymphocytic leukemia -- atrial fibrillation -- risk factors -- ibrutinib; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1257795
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age ( p < .0001), male sex ( p = .01), valvular heart disease ( p = .001), and hypertension ( p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% ( p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.